Sepsis and septic shock


State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with a high mortality and a significant economic burden to the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000 fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-05R device for patients with reduced body volume.

EAA™Endotoxin Activity Assay – is the only FDA approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.


Chronic kidney disease


A personalized therapy based on the individual needs of each patient


Acute kidney injury


HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on


ERA Congress 2022 – Paris & Virtual

The 59th ERA congress (European Renal Association) will be held from 19-22 May 2022 in Paris.
TORAY is supporting the symposium entitled “À la carte Hemodialysis for Patient: PMMA Adsorptive Membrane” on May 21 at 9.45 to 10.45.


Seminario ANTE 2022 – Riccione

The Seminario ANTE (National Association of Hemodialysis Technicians) will take place from 9-11 May 2022 in Riccione.
On May 9 we are supporting the symposium entitled “Immunonefrologia: la membrana dialitica come strategia terapeutica”.



The 33rd SMART Meeting (Smart Meeting Anesthesia Resuscitation Intensive Care) will take place May 4-6, 2022 in Milan – MiCO.
We are partnering with SMART and on May 4 we will support the WeSmart Session “Enhancing Strategies for Reducing VILI: Role of Mini-invasive CO2-removal” and on May 5 the Lunch Symposium entitled: “Endotoxemia in Critically Ill Patients and Advanced Blood Purification Therapies”